Page 12 - Exscientia News Today

Exscientia’s IPO and private placement raised $464 million to support its artificial intelligence-based approach to discovering and developing new drugs. In addition to partnerships with pharmaceutical companies, an alliance with the Bill & Melinda Gates Foundation is focused on developing antiviral drugs for future pandemics.

Exscientia plc (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, today announced the

11个月，AI刷新药物研发的速度

First candidate in multi-target collaboration to reach in-license milestone BMS to take responsibility for clinical and commercial development Exscientia receives $20 million option exercise

Édition digitale de Mons L’affiche. - D.R. À l’occasion de la première mondiale de sa pièce « La dernière nuit du monde » dans le cadre de la programmation « C’est l’été sur Mars » de Mons Arts de la Scène, le romancier et dramaturge Laurent Gaudé sera présent à Mons ce jeudi 1er juillet. Avant la représentation, prévue à 20h au théâtre Le Manège, Laurent Gaudé sera présent à la librairie Scientia à Mons pour une dédicace exclusive, qui aura lieu le jeudi 1...

Drug candidate is being evaluated for the treatment of Alzheimers disease psychosis - News - PharmaTimes

Second clinical molecule from Exscientia collaboration with Sumitomo Dainippon Pharma to begin Phase 1 trials in United States. Clinical study of DSP-0038, a dual targeted 5-HT1A agonist and 5-HT2A

Exscientia Announces Investment of up to $525M Proceeds to continue expansion of proprietary pipeline and end-to-end AI drug discovery capabilities $225 million Series D round closed with access up to an additional $300 million at Exscientias discretion Financing led by SoftBank Vision Fund 2 Exscientia, a clinical stage pharmatech company using artificial intelligence (AI) to design patient-based drugs, announced that it has completed a $225 million Series D funding round. SoftBank Vision Fund...

Making a difference with art Updated: Updated: March 04, 2021 23:27 IST An assessment done on students of Different Arts Centre in Thiruvananthapuram brings the perks of art therapy to light Share Article Students of Different Arts Centre, with its founder Gopinath Muthukad   An assessment done on students of Different Arts Centre in Thiruvananthapuram brings the perks of art therapy to light Amal Ajayakumar is in his late teens; though basic communication is a challenge for him, Amal is a w...

Oxford University to develop Alzheimer’s disease treatments with Exscientia 19th February 2021 The Alzheimer’s Research UK Oxford Drug Discovery Institute (ARUK-ODDI) has announced a partnership with AI drug discovery company Exscientia on the development of therapies for Alzheimer’s disease. The collaboration will focus on the NLRP3 inflammasome pathway, which has been shown to play a key role in Alzheimer’s pathogenesis. Exscientia will use its AI-driven technology to generate novel c...